Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial

Diabetic peripheral neuropathy (DPN) is the most common microvascular complication of diabetes that affects approximately half of the diabetic population. Up to 53% of DPN patients experience neuropathic pain, which leads to a reduction in the quality of life and work productivity. Tocotrienols have...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pei Fen Chuar, Yeek Tat Ng, Sonia Chew Wen Phang, Yan Yi Koay, J-Ian Ho, Loon Shin Ho, Nevein Philip Botross Henien, Badariah Ahmad, Khalid Abdul Kadir
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	type 2 diabetes mellitus (T2DM) diabetic peripheral neuropathy tocotrienol vitamin E transforming growth factor beta-1 (TGFβ-1) vascular endothelial growth factor A (VEGF-A) Nutrition. Foods and food supply TX341-641
Acceso en línea:	https://doaj.org/article/f2abb8c3b6a74bf8bd9fad08f7ef0762
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f2abb8c3b6a74bf8bd9fad08f7ef0762
record_format	dspace
spelling	oai:doaj.org-article:f2abb8c3b6a74bf8bd9fad08f7ef07622021-11-25T18:33:54ZTocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial10.3390/nu131137702072-6643https://doaj.org/article/f2abb8c3b6a74bf8bd9fad08f7ef07622021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6643/13/11/3770https://doaj.org/toc/2072-6643Diabetic peripheral neuropathy (DPN) is the most common microvascular complication of diabetes that affects approximately half of the diabetic population. Up to 53% of DPN patients experience neuropathic pain, which leads to a reduction in the quality of life and work productivity. Tocotrienols have been shown to possess antioxidant, anti-inflammatory, and neuroprotective properties in preclinical and clinical studies. This study aimed to investigate the effects of tocotrienol-rich vitamin E (Tocovid Suprabio<sup>TM</sup>) on nerve conduction parameters and serum biomarkers among patients with type 2 diabetes mellitus (T2DM). A total of 88 patients were randomized to receive 200 mg of Tocovid twice daily, or a matching placebo for 12 months. Fasting blood samples were collected for measurements of HbA1c, renal profile, lipid profile, and biomarkers. A nerve conduction study (NCS) was performed on all patients at baseline and subsequently at 2, 6, 12 months. Patients were reassessed after 6 months of washout. After 12 months of supplementation, patients in the Tocovid group exhibited highly significant improvements in conduction velocity (CV) of both median and sural sensory nerves as compared to those in the placebo group. The between-intervention-group differences (treatment effects) in CV were 1.60 m/s (95% CI: 0.70, 2.40) for the median nerve and 2.10 m/s (95% CI: 1.50, 2.90) for the sural nerve. A significant difference in peak velocity (PV) was also observed in the sural nerve (2.10 m/s; 95% CI: 1.00, 3.20) after 12 months. Significant improvements in CV were only observed up to 6 months in the tibial motor nerve, 1.30 m/s (95% CI: 0.60, 2.20). There were no significant changes in serum biomarkers, transforming growth factor beta-1 (TGFβ-1), or vascular endothelial growth factor A (VEGF-A). After 6 months of washout, there were no significant differences from baseline between groups in nerve conduction parameters of all three nerves. Tocovid at 400 mg/day significantly improve tibial motor nerve CV up to 6 months, but median and sural sensory nerve CV in up to 12 months of supplementation. All improvements diminished after 6 months of washout.Pei Fen ChuarYeek Tat NgSonia Chew Wen PhangYan Yi KoayJ-Ian HoLoon Shin HoNevein Philip Botross HenienBadariah AhmadKhalid Abdul KadirMDPI AGarticletype 2 diabetes mellitus (T2DM)diabetic peripheral neuropathytocotrienolvitamin Etransforming growth factor beta-1 (TGFβ-1)vascular endothelial growth factor A (VEGF-A)Nutrition. Foods and food supplyTX341-641ENNutrients, Vol 13, Iss 3770, p 3770 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes mellitus (T2DM) diabetic peripheral neuropathy tocotrienol vitamin E transforming growth factor beta-1 (TGFβ-1) vascular endothelial growth factor A (VEGF-A) Nutrition. Foods and food supply TX341-641
spellingShingle	type 2 diabetes mellitus (T2DM) diabetic peripheral neuropathy tocotrienol vitamin E transforming growth factor beta-1 (TGFβ-1) vascular endothelial growth factor A (VEGF-A) Nutrition. Foods and food supply TX341-641 Pei Fen Chuar Yeek Tat Ng Sonia Chew Wen Phang Yan Yi Koay J-Ian Ho Loon Shin Ho Nevein Philip Botross Henien Badariah Ahmad Khalid Abdul Kadir Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial
description	Diabetic peripheral neuropathy (DPN) is the most common microvascular complication of diabetes that affects approximately half of the diabetic population. Up to 53% of DPN patients experience neuropathic pain, which leads to a reduction in the quality of life and work productivity. Tocotrienols have been shown to possess antioxidant, anti-inflammatory, and neuroprotective properties in preclinical and clinical studies. This study aimed to investigate the effects of tocotrienol-rich vitamin E (Tocovid Suprabio<sup>TM</sup>) on nerve conduction parameters and serum biomarkers among patients with type 2 diabetes mellitus (T2DM). A total of 88 patients were randomized to receive 200 mg of Tocovid twice daily, or a matching placebo for 12 months. Fasting blood samples were collected for measurements of HbA1c, renal profile, lipid profile, and biomarkers. A nerve conduction study (NCS) was performed on all patients at baseline and subsequently at 2, 6, 12 months. Patients were reassessed after 6 months of washout. After 12 months of supplementation, patients in the Tocovid group exhibited highly significant improvements in conduction velocity (CV) of both median and sural sensory nerves as compared to those in the placebo group. The between-intervention-group differences (treatment effects) in CV were 1.60 m/s (95% CI: 0.70, 2.40) for the median nerve and 2.10 m/s (95% CI: 1.50, 2.90) for the sural nerve. A significant difference in peak velocity (PV) was also observed in the sural nerve (2.10 m/s; 95% CI: 1.00, 3.20) after 12 months. Significant improvements in CV were only observed up to 6 months in the tibial motor nerve, 1.30 m/s (95% CI: 0.60, 2.20). There were no significant changes in serum biomarkers, transforming growth factor beta-1 (TGFβ-1), or vascular endothelial growth factor A (VEGF-A). After 6 months of washout, there were no significant differences from baseline between groups in nerve conduction parameters of all three nerves. Tocovid at 400 mg/day significantly improve tibial motor nerve CV up to 6 months, but median and sural sensory nerve CV in up to 12 months of supplementation. All improvements diminished after 6 months of washout.
format	article
author	Pei Fen Chuar Yeek Tat Ng Sonia Chew Wen Phang Yan Yi Koay J-Ian Ho Loon Shin Ho Nevein Philip Botross Henien Badariah Ahmad Khalid Abdul Kadir
author_facet	Pei Fen Chuar Yeek Tat Ng Sonia Chew Wen Phang Yan Yi Koay J-Ian Ho Loon Shin Ho Nevein Philip Botross Henien Badariah Ahmad Khalid Abdul Kadir
author_sort	Pei Fen Chuar
title	Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial
title_short	Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial
title_full	Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial
title_fullStr	Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial
title_full_unstemmed	Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial
title_sort	tocotrienol-rich vitamin e (tocovid) improved nerve conduction velocity in type 2 diabetes mellitus patients in a phase ii double-blind, randomized controlled clinical trial
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f2abb8c3b6a74bf8bd9fad08f7ef0762
work_keys_str_mv	AT peifenchuar tocotrienolrichvitaminetocovidimprovednerveconductionvelocityintype2diabetesmellituspatientsinaphaseiidoubleblindrandomizedcontrolledclinicaltrial AT yeektatng tocotrienolrichvitaminetocovidimprovednerveconductionvelocityintype2diabetesmellituspatientsinaphaseiidoubleblindrandomizedcontrolledclinicaltrial AT soniachewwenphang tocotrienolrichvitaminetocovidimprovednerveconductionvelocityintype2diabetesmellituspatientsinaphaseiidoubleblindrandomizedcontrolledclinicaltrial AT yanyikoay tocotrienolrichvitaminetocovidimprovednerveconductionvelocityintype2diabetesmellituspatientsinaphaseiidoubleblindrandomizedcontrolledclinicaltrial AT jianho tocotrienolrichvitaminetocovidimprovednerveconductionvelocityintype2diabetesmellituspatientsinaphaseiidoubleblindrandomizedcontrolledclinicaltrial AT loonshinho tocotrienolrichvitaminetocovidimprovednerveconductionvelocityintype2diabetesmellituspatientsinaphaseiidoubleblindrandomizedcontrolledclinicaltrial AT neveinphilipbotrosshenien tocotrienolrichvitaminetocovidimprovednerveconductionvelocityintype2diabetesmellituspatientsinaphaseiidoubleblindrandomizedcontrolledclinicaltrial AT badariahahmad tocotrienolrichvitaminetocovidimprovednerveconductionvelocityintype2diabetesmellituspatientsinaphaseiidoubleblindrandomizedcontrolledclinicaltrial AT khalidabdulkadir tocotrienolrichvitaminetocovidimprovednerveconductionvelocityintype2diabetesmellituspatientsinaphaseiidoubleblindrandomizedcontrolledclinicaltrial
_version_	1718410988251774976

Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial

Ejemplares similares